AlTi Tiedemann Global Closes Previously Announced Envoi Acquisition
AlTi Tiedemann Global Closes Previously Announced Envoi Acquisition
AlTi Global, Inc. (NASDAQ: ALTI), (“AlTi”), a leading independent global wealth and alternatives manager with over $70 billion in combined assets, today completed the previously announced acquisition of Envoi, LLC a Minneapolis-based family office focused on multi-generational family wealth with assets under management (AUM) of approximately $3.0 billion.
About AlTi
AlTi is a leading independent global wealth and alternatives manager providing entrepreneurs, multi-generational families, institutions, and emerging next-generation leaders with fiduciary capabilities as well as alternative investment strategies and advisory services. AlTi’s comprehensive offering is underscored by a commitment to impact or values-aligned investing. The firm currently manages or advises on over $70 billion in combined assets and has an expansive network with approximately 400 professionals across three continents. For more information, please visit us at www.alti-global.com.
Investor Relations:
Lily Arteaga, Head of Investor Relations
investor@alti-global.com
Media Relations:
Alex Jorgensen, pro-alti@prosek.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701389679/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks